EMA Relocation: EU Approval Delays Cannot Be Ruled Out
Now that the European Medicines Agency knows where it is going after Brexit, the business of preparing for the move can begin. Being able to ensure business continuity during and after the relocation from London to Amsterdam will be highly dependent on the EMA’s ability to retain as many of its current staff as possible. Job losses are expected but it could be some time before it’s clear which business operations will be affected.
You may also be interested in...
A press conference following the announcement that the European Medicines Agency is to move from London to Amsterdam included a series of questions on the selection process and the voting itself.
The EMA has published its analysis of the 19 bids to host the agency post-Brexit, which confirms reports that five cities – Amsterdam, Barcelona, Copenhagen, Milan and Vienna – would bring the best result in terms of retaining staff when it relocates. The agency has expressed concern that low retention rates could hit operations and result in lower fee income, requiring an injection of cash from the EU budget.
With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.